Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A0 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Shattuck Labs, Inc. NASDAQ:STTK | $560.31M | $6.20 | Not rated | -10.9 | +135.75% |
InflaRx N.V. NASDAQ:IFRX | $307.84M | $2.09 | Not rated | -2.7 | -5.22% |
MacroGenics, Inc. NASDAQ:MGNX | $254.25M | $4.00 | Not rated | -3.6 | +44.53% |
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | $249.86M | $3.51 | Not rated | -2.1 | +4.62% |
Whitehawk Therapeutics Inc NASDAQ:WHWK | $234.31M | $4.11 | Not rated | -2.6 | +56.78% |
Surrozen, Inc. NASDAQ:SRZN | $142.07M | $19.00 | Not rated | -0.7 | +123.22% |
Oncolytics Biotech Inc. NASDAQ:ONCY | $74.82M | $0.75 | Not rated | -4.3 | -49.34% |
Pliant Therapeutics, Inc. NASDAQ:PLRX | $72.45M | $1.17 | Not rated | -0.6 | -48.10% |
Continue the stock analysis
Jump to another research area for this company.